RaymondsIndex

Two markets crossed the same kind of line last week, using opposite mechanics. Side by side, they define relational risk better than either does alone. The line you cannot touch On July 28, KRX data showed eleven Korean listed companies designated as 관리종목 (administrative issue) during July for failing the market-capitalisation floor — ten on KOSDAQ, one on KOSPI. The mechanism is arithmetic: 30 consecutive sessions below ₩20bn on KOSDAQ triggers designation; failing to clear the bar for 45 consecutive sessions within the following 90 triggers delisting. The floor rises again to ₩30bn on KOSDAQ and ₩50bn on KOSPI in the first half of 2027. On July 27 the exchange disclosed that five more names had been below the line for 25 consecutive sessions and would be designated if that held five more. Then the case worth pausing on. 졸스 hit the same 25-session mark on July 22. The next day the share price rose, the closing market cap printed ₩20.5bn, and the designation risk lapsed. Operations ...

On 7 July the Korea Exchange published its monthly update on corporate value-up disclosure. The number that travelled was 85.5% — the share of total market capitalisation represented by companies that have filed a value-up plan since the programme began in May 2024. Underneath it: 741 companies cumulatively, 347 on KOSPI and 394 on KOSDAQ, with 12 new filers in June. Two other figures in the same release did not travel. First, the coverage number splits sharply by market — 89.4% of KOSPI capitalisation, 32.5% of KOSDAQ. Second, the number of companies that have submitted a periodic filing including an assessment of how the earlier plan actually went: 116. Tokyo's version of this looks much the same from a distance. The Tokyo Stock Exchange asked Prime and Standard Market companies in March 2023 to disclose actions reflecting cost of capital and share price. Prime Market disclosure passed 90% by March 2025, Standard sat near 50% as of April 2026, and more than 60% of respondents h...

On 30 July 2026, Enex Co. (KOSPI: 011090), a Korean kitchen-furniture manufacturer listed since 1995, disclosed that its controlling shareholder Park Jin-kyu and seven others had agreed to transfer 3,377,388 common shares — 28.48% of the company — to a vehicle named the Enex Future Growth Partnership. The price: ₩11,483,119,200. Read the payment schedule, though, and the deal thins out. ₩1.0bn was paid on signing. The remaining ₩10.48bn falls due on 4 September, and only "on the premise that all conditions precedent under the contract are satisfied." Nine days earlier, on 21 July, the company had approved a ₩5.0bn third-party placement — 2 million new shares at ₩2,500 to Queenver Mezzanine No.1 Partnership. The shares closed that same session at ₩1,458, down 24.46% on the day. Set against those two forward-looking promises is one backward-looking certainty. In December 2025 the Korea Fair Trade Commission provisionally levied ₩25.0bn in penalties on 48 furniture makers over...

On 30 July 2026, Korea's Financial Supervisory Service published its comprehensive plan to overhaul pharmaceutical and biotech disclosure. The reform is unusually specific about a single number: the total value of a technology-transfer agreement. Under the new framework, a licensing deal can no longer be disclosed as one figure. Companies must break it into four lines — upfront payment, development milestones, approval and sales milestones, and royalties — and state the payment condition and character of each. The FSS was explicit about why: because only the total was published, milestones and royalties, which are payable solely on the satisfaction of conditions, were being read as amounts already secured at signing. The reform reaches further back than that. At the IPO stage, the assumptions behind a valuation must now be set out in four standardised categories: expected market size, probability of clinical success, approval and review risk, and development period and cost. Expe...

Two corporate decisions landed within days of each other in late July 2026, and between them they expose how badly the market reads reinvestment. On 27 July, Japan's Seven & i Holdings confirmed it had walked away from talks to take a stake in Żabka Group, the largest convenience store operator in Poland. Reporting put the contemplated stake at several tens of a percent and the transaction value in the hundreds of billions of yen. Seven & i's explanation was unusually plain: it could not reach agreement with the seller on terms it considered to be in the interest of its shareholders and other stakeholders. This was not a company without ambition. It is publicly targeting growth from roughly 87,000 stores to 100,000 by 2030, and its European footprint is currently thin — around 360 stores concentrated in the Nordics. Żabka would have been a Central European foothold with 10,000 franchised stores and 27.15bn zlotys ($7.16bn) of revenue in the twelve months to December 202...

 On 24 July 2026, SK Inc. disclosed a tender offer for SK Signet, its EV fast-charger subsidiary listed on Korea's KONEX market. The terms are unremarkable on their face: ₩8,200 per common and convertible preferred share, more than a 20% premium to the one-month volume-weighted average price, for up to 10,072,587 shares — about ₩82.6bn if fully taken up. The offer runs 24 July to 24 August, settling 26 August. SK's voting stake rises from 66.71% to an expected 99.77%, with any stub acquired through a comprehensive share exchange. Delisting and full-subsidiary status are targeted for the fourth quarter; a sale of the unit, for the first quarter of 2027. SK's own framing is portfolio rebalancing: clear a non-core asset, free up investment capacity. The company also noted that a share exchange alone would have achieved 100% ownership, and that running a premium tender first was a shareholder-protection choice. Both statements are defensible. What makes this a capital efficie...